Mallinckrodt FY2023 net sales $1.87B, EBITDA $572M; guides FY2024 EBITDA $520-560M

Keenova Therapeutics plc

FY2023 net sales $1.866B, down 2.5% YoY; Q4 net sales $469.3M (-4.1%).
FY2023 Adjusted EBITDA $571.9M, above guidance range; Q4 EBITDA $123.8M vs $175.5M.
Specialty Brands Q4 net sales $270.7M (-15.6%); impacted by Amitiza generic competition.
Specialty Generics Q4 net sales $198.6M (+17.8%); strong finished-dosage demand.
2024 guidance: net sales $1.80-1.90B, Adj. EBITDA $520-560M; FDA approved SelfJect injector.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Keenova Therapeutics plc updated its the fourth quarter and fiscal year ended December 29, 2023 guidance (raised).

Period: the fourth quarter and fiscal year ended December 29, 2023
Guidance: raised
Result: reported results

Exact text from the filing

On March 26, 2024, Mallinckrodt plc provided its financial results for the three months and year ended December 29, 2023 as set forth in the attached Exhibit 99.1.

View on SEC.gov

326 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001567892-24-000007

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.